Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component

Biologic basis for interleukin-1 in disease

1996 • 4,324 citations

Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension

1989 • 3,067 citations

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

2003 • 2,200 citations

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

1988 • 1,698 citations

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

2007 • 840 citations

Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6

1989 • 775 citations

Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]

1993 • 321 citations

C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system

1992 • 296 citations

Interleukin 6 is essential for in vivo development of B lineage neoplasms.

1995 • 233 citations

Thalidomide as initial therapy for early-stage myeloma

2003 • 231 citations

Initial versus deferred melphalan‐prednisone therapy for asymptomatic multiple myeloma stage I — A randomized study

1993 • 219 citations

Role of NF-κB in the Rescue of Multiple Myeloma Cells From Glucocorticoid-Induced Apoptosis by Bcl-2

1999 • 202 citations

Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266

1991 • 177 citations

Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma

1988 • 176 citations

Risk of disease progression in asymptomatic multiple myeloma

1993 • 157 citations

Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma

1983 • 153 citations

Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma

1988 • 146 citations

The paradox of response and survival in cancer therapeutics

2005 • 145 citations

Prognostic features of asymptomatic multiple myeloma

1997 • 124 citations

Immunofluorescence Labeling Indices in Myeloma and Related Monoclonal Gammopathies

1987 • 99 citations

Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma

1994 • 94 citations

In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma

1991 • 91 citations

THE ROLE OF INTERLEUKIN-1β IN THE PATHOGENESIS OF MULTIPLE MYELOMA

1999 • 86 citations

Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6.

1996 • 86 citations

Comparison of Interleukin-1β Expression by In Situ Hybridization in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

1999 • 82 citations

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

2014 • 72 citations

Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders

1999 • 66 citations

Incidence and follow‐up of asymptomatic multiple myeloma.

1991 • 44 citations

Identification of Two Groups of Smoldering Multiple Myeloma Patients Who Are Either High or Low Producers of Interleukin-1

2006 • 44 citations

Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma

1998 • 41 citations

Prognostic factors in low tumour mass asymptomatic multiple myeloma: A report on 91 patients

1995 • 38 citations

Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

2007 • 30 citations

Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma.

1995 • 21 citations

Treatment of multiple myeloma: An emphasis on new developments

2006 • 16 citations

Final Analysis of a Multicenter, Randomised Study Comparing Zoledronate vs Observation in Patients with Asymptomatic Myeloma.

2007 • 5 citations

Immunoglobulin Free Light Chain Ratio Is an Independent Risk Factor for Progression of Smoldering Multiple Myeloma.

2007 • 3 citations